Autologous cytotoxic T lymphocyte therapy was effective for M-VAC-refractory invasive bladder cancer

BJUI ◽  
2012 ◽  
Author(s):  
Kogenta Nakamura ◽  
Kazuhiro Yoshikawa ◽  
Yoshiaki Yamada ◽  
Makoto Sumitomo
Keyword(s):  
Bladder Cancer ◽  
T Lymphocyte ◽  
Cytotoxic T Lymphocyte ◽  
Invasive Bladder Cancer

scholarly journals Expression of FOXA1 Is Associated with the Tumor-Infiltrating M2 Macrophage, Cytotoxic T Lymphocyte, and Effect of Chemotherapy in Bladder Cancer

2021 ◽  
pp. 1-6
Author(s):  
Yiduo Wang ◽  
Huan Qu ◽  
Bin Xu ◽  
Jianping Wu ◽  
Kai Lu ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Response ◽  
T Lymphocyte ◽  
Objective Response Rate ◽  
Immune Cell ◽  
Response Rate ◽  
Cytotoxic T Lymphocyte ◽  
Objective Response ◽  
Immune Cell Infiltration ◽  
Foxa1 Expression

Purpose: Cisplatin-containing combination chemotherapy has been the standard of care since the late 1980s, but the response rate is <50%. Studies have shown that the efficiency of chemotherapy differs among molecular subtypes of bladder cancer. In this study, we aimed to correlate FOXA1, a marker for differentiation of the basal and luminal subtypes, with tumor immune cell infiltration and the effect of chemotherapy in bladder cancer. Materials and Methods: Eighty-three patients with bladder cancer treated with chemotherapy were reviewed. Clinicopathological variables for each case were recorded. FOXA1, M2 tumor-associated macrophage (TAM), dendritic cell (DC), and cytotoxic T lymphocyte (CTL) were examined by immunohistochemistry. The relationship between FOXA1, immune cell infiltration, and clinical response to chemotherapy was assessed. Results: The overall objective response rate was 34%. The objective response rate for tumors with lower FOXA1 expression was 58% and for tumors with higher FOXA1 expression was 12%. Tumors with infiltrated M2 TAM proportion <3% had a higher objective response rate compared with infiltrated M2 TAM proportion >3% tumors (46% vs. 21%, p = 0.02). Tumors with infiltrated CTL proportion >5% had a higher objective response rate compared with infiltrated CTL proportion <5% tumors (50% vs. 17%, p = 0.002). DCs showed no significant differences. We found that the objective response rate for tumors with lower FOXA1 expression, proportion <3% M2 TAM infiltration, and proportion >5% CTL infiltration is 82%. Lower FOXA1 expression was associated with low M2 TAM infiltration and high CTL infiltration. Conclusions: Thus, we showed that in patients with bladder cancer who received chemotherapy, the higher clinical response rate is associated with low FOXA1 expression, low M2 TAM infiltration, and high CTL infiltration.

scholarly journals Progress in Research on Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) and Bladder Cancer

2019 ◽  
pp. 1-7 ◽  
Author(s):  
Wei-Ming Fang ◽  
Chun Chen
Keyword(s):  
Monoclonal Antibody ◽  
Bladder Cancer ◽  
T Cells ◽  
T Lymphocyte ◽  
First Generation ◽  
Cytotoxic T Lymphocyte ◽  
Inhibit Tumor Growth ◽  
Igg1 Monoclonal Antibody ◽  
Antigen Presenting ◽  
Important Therapeutic Target

Cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) was first discovered in 1987 and confirmed to be a protein that is mainly expressed on the surface of activated lymphocytes. CTLA-4 is expressed on the surface of T cells and binds to B7 expressed on antigen presenting cells(APCs) to potentially play a role in inhibiting lymphocyte proliferation. Inhibitors of CTLA-4 were developed to promote the anti-tumor effects of T cells and inhibit tumor growth. CTLA-4, as an immune checkpoint, has been realized as an important therapeutic target in bladder cancer. Two main CTLA-4 inhibitors are currently used: ipilimumab is a first-generation IgG1 monoclonal antibody that targets CTLA-4, and it is completely synthetic; tremelimumab, representing another class of CTLA-4 inhibitors, is a monoclonal antibody against CTLA-4 that acts similarly to ipilimumab and binds specifically to CTLA-4. The two types of CTLA-4 inhibitors were found to improve the treatment effect in patients with bladder cancer in comparison to conventional agents. To review this topic, we searched recently published related articles.

Association between the cytotoxic T-lymphocyte antigen 4 +49A/G polymorphism and bladder cancer risk

Tumor Biology ◽  
2013 ◽  
Vol 35 (2) ◽  
pp. 1139-1142 ◽  
Author(s):  
Lei Wang ◽  
Guixiang Su ◽  
Xinghua Zhao ◽  
Yi Cai ◽  
Xianan Cai ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Risk ◽  
T Lymphocyte ◽  
Cytotoxic T Lymphocyte ◽  
Bladder Cancer Risk ◽  
Lymphocyte Antigen

Sex and Racial Disparities in the Treatment and Outcomes of Muscle-invasive Bladder Cancer

Urology ◽  
2020 ◽  
Author(s):  
Jessica Marinaro ◽  
Alexander Zeymo ◽  
Jillian Egan ◽  
Filipe Carvalho ◽  
Ross Krasnow ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Racial Disparities ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

339: Selective Bladder Preservation by Transurethral Layer-Section in T2 Muscle-Invasive Bladder Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 114-115
Author(s):  
Young Deuk Choi ◽  
Kang Su Cho ◽  
Soung Yong Cho ◽  
Hyun Min Choi ◽  
Nam Hoon Cho
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Bladder Preservation ◽  
Muscle Invasive
Sign in / Sign up

Export Citation Format

Share Document